Galski- Lorberboum Haya Projects

Background   Considerable efforts have been invested in recent years in developing new, effective, yet less toxic drugs for targeted cancer therapy. Currently, this diverse group of drugs includes monoclonal antibodies, immunomodulators, ...

  Background DNA mutations in mitochondrial proteins/enzymes (nuclear encoded) that may lead to disease are present in approximately 1 in 8,000 individuals. Any treatment for mitochondrial diseases must be capable of targeting and crossing the ...